Anupam Rama
JPMorgan Chase & Co, Research Division
Welcome to the 44th Annual JPMorgan Healthcare Conference. My name is Anupam Rama. I am one of the senior biotech analysts here at JPMorgan.
I’m joined by my squad, Priyanka Grover, Joyce Zhou, and Rati Pinge. Our next presenting company is Biomea Fusion. And presenting on behalf of the company, we have CEO, Mick Hitchcock.
Michael J. Hitchcock
Interim CEO & Director
Yes. Thanks a lot. Good afternoon, everybody. Thanks for coming. I want to thank JPMorgan for putting on the conference and for inviting us to give a presentation so that everyone can see what we’re doing.
Also, just for context, my name is Mick Hitchcock. I’m CEO of the company. I’ve been on board since about March, and I’ll jump right into the presentation.
First, of course, is the legal disclaimer. And I think you’ve probably seen enough of these after 3 days that I don’t need to dwell on it.
I think everybody knows what it says. So in terms of what Biomea Fusion is working on currently, we are developing 2 assets, and we believe that they’re both significant contributors to our new focus, which is diabetes and obesity.
Icovamenib specifically at this point is targeted at diabetes. It’s an oral small molecule. And what I’ll talk to you about is some data that we got out of this Covalent 111 study and then tell you about the 2 patient populations that we have significant activity in and then talk about where we’re going next.
On the other
